Transcarent Stock

transcarent.aiHealthcare / Healthcare providers & servicesFounded: 2018Funding to Date: $1.1B

Transcarent is a digital health company that offers a healthcare technology platform striving to simplify and improve healthcare experiences and outcomes for employers and their employees. The company’s mission is to provide high-quality, affordable, and accessible care. Transcarent was founded in 2020 and is headquartered in Denver, CO. Transcarent also has a consumer-facing mobile app, an on-demand care team, and a network of pre-screened healthcare providers with which the company has direct contracts.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Transcarent, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Transcarent Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Transcarent Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
03/07/2024 Series D $150MM $xx.xx $1.87B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
7,325,631
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
01/11/2022 Series C $200MM $xx.xx $1.62B 7wireventures, Ally Bridge Group, Alta Partners, General Catalyst, Greatpoint Ventures, Human Capital, Intermountain Healthcare, Jove Equity Partners, Kinnevik, Merck Global Health Innovation Fund, Northwell Health, Rush University Medical Center, Threshold Ventures
Price per Share
$xx.xx
Shares Outstanding
10,521,808
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
7wireventures, Ally Bridge Group, Alta Partners, General Catalyst, Greatpoint Ventures, Human Capital, Intermountain Healthcare, Jove Equity Partners, Kinnevik, Merck Global Health Innovation Fund, Northwell Health, Rush University Medical Center, Threshold Ventures
06/10/2021 Series B $58MM $xx.xx $468.55MM 7wireventures, Alta Partners, General Catalyst, Greatpoint Ventures, Jove Equity Partners, Kleiner Perkins, Leaps Bybayer, Merck Global Health Innovation Fund, Threshold Ventures
Price per Share
$xx.xx
Shares Outstanding
9,589,915
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
7wireventures, Alta Partners, General Catalyst, Greatpoint Ventures, Jove Equity Partners, Kleiner Perkins, Leaps Bybayer, Merck Global Health Innovation Fund, Threshold Ventures
10/22/2020 Series A-2 $163,838.15 $xx.xx $231.54MM 7wire Ventures, Alta Partners, General Catalyst, Jove Equity Partners
Price per Share
$xx.xx
Shares Outstanding
167,371
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
7wire Ventures, Alta Partners, General Catalyst, Jove Equity Partners
10/22/2020 Series A $25.89MM $xx.xx $231.54MM 7wire Ventures, Alta Partners, General Catalyst, Jove Equity Partners
Price per Share
$xx.xx
Shares Outstanding
15,148,291
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
7wire Ventures, Alta Partners, General Catalyst, Jove Equity Partners
10/22/2020 Series A-1 $13.95MM $xx.xx $231.54MM 7wire Ventures, Alta Partners, General Catalyst, Jove Equity Partners
Price per Share
$xx.xx
Shares Outstanding
4,389,220
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
7wire Ventures, Alta Partners, General Catalyst, Jove Equity Partners
08/15/2018 Series Seed $3MM $xx.xx $30.8MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
6,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
08/15/2018 Series Seed-2 $3.37MM $xx.xx $30.8MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
3,440,641
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

Transcarent Investors Also Invested in These Private Companies

Merck Global Health Innovation Fund
Intermountain Ventures
50 South Capital Advisors
Northwell Holdings
Rush University System for Health
Wasson Enterprise

Leadership & Board

Leadership

Glen Tullman
Chief Executive Officer
Snezana Mahon
Chief Operating Officer
Stephanie Peng
Chief Financial Officer
Caitlin Fleming
Chief Strategy Officer
Randy Hawkins M.D.
Chief Medical Officer
Janine Gianfredi
Chief Marketing Officer
Zoë Harte
Chief People Officer
Praful Kaul
Chief Technology Officer
Jason Macaleer
Chief Commercial Officer
Rachel Stillman
Chief of Staff

Board

David Calone
Jove Equity Partners
Holly Maloney
General Catalyst

Transcarent stock FAQs

plusminus

Can you buy Transcarent stock?

As Transcarent is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Transcarent, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Transcarent stock?

To invest in a private company like Transcarent through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Transcarent stock?

Yes, you may sell the Transcarent stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Transcarent stock?

If you hold private company shares of Transcarent – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Transcarent on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Transcarent a public company?

No, Transcarent is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Transcarent’s stock price?

Transcarent is a privately held company and therefore does not have a public stock price. However, you may access Transcarent private market stock price with Forge Data.
plusminus

What is Transcarent’s stock ticker symbol?

Transcarent does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Transcarent News and Media Highlights

Digital health startup Transcarent valued at $2.2 bln after latest funding round

In a series D funding round led by General Catalyst and 7wireVentures, Transcarent raised $126 million.

Health Startup Transcarent Is Raising a $125 Million

Transcarent is looking to raise $125 million, bringing its valuation to $2.1 billion.

Trans healthcare startup Plume lays off dozens of workers

Plume, a US-based telehealth startup focusing on trans healthcare, has reportedly laid off around one-sixth of its workforce. The company raised $24m in a series B funding round last year and offers online healthcare services to transgender patients, a demographic often facing significant healthcare barriers. Despite the layoffs, Plume confirmed it will not scale back its services and plans to expand its fee-for-service offerings.

Transcarent Partners With 10 Health Systems To Launch Provider Network

"Transcarent, a care navigation company, has partnered with 10 health systems to launch a new provider network. The network aims to help employer customers provide affordable, high-quality care to their staff. The health systems in the network include Mount Sinai, Mass General Brigham, and Intermountain Health. Transcarent's platform allows patients to access care online, schedule appointments, arrange home visits from providers, access specialists, and order prescription delivery. The company was last valued at $1.62 billion in 2022.
Browse Insights
Updated on: Dec 17, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.